Drug Profile
LY 2624587
Alternative Names: LY2624587Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Cancer(Late-stage disease, Metastatic disease) in USA (IV)
- 23 Jan 2012 Eli Lilly completes a phase I trial in Cancer in the US (NCT01139788)
- 30 Jun 2010 Phase-I clinical trials in Cancer in USA (IV)